Carly Campbell

Carly Campbell has extensive experience in translational science and biology, currently serving as Principal Scientist at Bicycle Therapeutics since March 2019, where previous responsibilities included Senior Scientist in the same department. Prior experience at Epizyme from April 2010 to March 2019 encompassed roles from Scientist to Principal Research Associate, focusing on the development of a novel histone methyltransferase DOT1L inhibitor, culminating in the Phase 1 clinical compound pinometostat. Earlier roles include Research Associate at Repligen and multiple research positions at Tufts University, including a student researcher role. Carly Campbell earned a Bachelor of Science in Biochemistry from Tufts University between 2004 and 2007.